Bristol Advisors LLC bought a new position in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,700 shares of the company’s stock, valued at approximately $228,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Accredited Investors Inc. raised its holdings in shares of Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after acquiring an additional 14 shares during the last quarter. Oakworth Capital Inc. raised its holdings in shares of Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the last quarter. Sfmg LLC increased its stake in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after buying an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after buying an additional 24 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC increased its stake in Eli Lilly and by 0.8% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after buying an additional 24 shares during the last quarter. Institutional investors own 76.31% of the company’s stock.

Several research firms have commented on LLY. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and increased their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 12th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average price target of $92.14.

In related news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 251,088 shares of company stock valued at $22,041,236. 0.20% of the stock is owned by insiders.

Eli Lilly and Co (LLY) traded up $0.29 during trading on Friday, hitting $86.39. 2,647,400 shares of the stock were exchanged, compared to its average volume of 2,742,913. Eli Lilly and Co has a 1 year low of $74.00 and a 1 year high of $89.09. The company has a market cap of $95,960.00, a P/E ratio of 41.14, a P/E/G ratio of 1.62 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period last year, the firm earned $0.88 EPS. research analysts expect that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.60%. Eli Lilly and’s dividend payout ratio (DPR) is 99.05%.

ILLEGAL ACTIVITY WARNING: “Bristol Advisors LLC Buys Shares of 2,700 Eli Lilly and Co (LLY)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/12/bristol-advisors-llc-buys-shares-of-2700-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.